A Blythe Ryerson

Dr. A Blythe Ryerson

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
AKAlain Koyama
Alain Koyama
EKEmilia H. Koumans
Emilia H. Koumans
KSKanta Sircar
Kanta Sircar
ALAmy Lavery
Amy Lavery
JHJoy Hsu
Joy Hsu
DSDavid A. Siegel
David A. Siegel
The aim of this study was to evaluate the association between intellectual and developmental disabilities (IDDs) and severe COVID-19 outcomes, 30-day readmission, and/or increased length of stay (LOS) using a large electronic administrative database. Patients hospitalized with COVID-19 were identified between March 2020 and June 2021 from more than 900 hospitals in the United States. IDDs included intellectual disability, cerebral palsy, Down syndrome, autism spectrum disorder (ASD), and other intellectual disabilities. Outcomes included intensive care unit (ICU) admission, invasive mechanical ventilation (IMV), 30-day readmission, mortality, and LOS. Among 643,765 patients with COVID-19, multivariate models showed that patients with any IDD were at a significantly greater risk of at least 1 severe outcome, 30-day readmission, or longer LOS than patients without any IDD. Compared with those without any IDD, patients with Down syndrome had the greatest odds of ICU admission (odds ratio [OR] and 95% confidence interval [CI]: 1.96 [1.73-2.21]), IMV (OR: 2.37 [2.07-2.70]), and mortality (OR: 2.33 [2.00-2.73]). Patients with ASD and those with Down syndrome both had over a 40% longer mean LOS. Patients with intellectual disabilities had a 23% (12-35%) increased odds of 30-day readmission. Results suggest that patients hospitalized with COVID-19 with IDD have a significantly increased risk of severe outcomes, 30-day readmission, and longer LOS.

14 October 2016 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
SSSimple D. Singh
Simple D. Singh
JHJane Henley
Jane Henley
ARA Blythe Ryerson
A Blythe Ryerson
This report provides, in tabular and graphic form, official federal statistics on the occurrence of cancer for 2012 and trends for 1999-2012 as reported by CDC and the National Cancer Institute (NCI) (1). Cancer incidence data are from population-based cancer registries that participate in CDC's National Program of Cancer Registries (NPCR) and NCI's Surveillance, Epidemiology, and End Results (SEER) program reported as of November 2014. Cancer mortality data are from death certificate information reported to state vital statistics offices through 2012 and compiled into a national file for the entire United States by CDC's National Center for Health Statistics' (NCHS) National Vital Statistics System (NVSS). This report is a part of the Summary of Notifiable Noninfectious Conditions and Disease Outbreaks - United States, which encompasses various surveillance years but is being published in 2016 (2). The Summary of Notifiable Noninfectious Conditions and Disease Outbreaks appears in the same volume of MMWR as the annual Summary of Notifiable Infectious Diseases (3).

18 August 2026 in Cancers
Verified
Journal Article
Open access
PDF file
APAmanda Petrik
Amanda Petrik
CJCharisma Jenkins
Charisma Jenkins
ARAna G Rosales
Ana G Rosales
TKTerry Kimes
Terry Kimes
NSNing Smith
Ning Smith
DMDavid Mosen
David Mosen
Background: It is well documented that Black and African American (AA) patients have the highest risk of recurrence of breast cancer. However, less is known about racial differences in gene expression profiling tests such as Oncotype DX that predicts cancer recurrence. This study aimed to assess the predictive differences in Oncotype DX scores for breast cancer outcomes between Black/AA and non-Hispanic White patients. Methods: We identified Oncotype DX testing status in patients ages 18–75 years who were newly diagnosed with breast cancer, assessed race and other factors among patients with different testing statuses, and described the distribution of the Oncotype DX score. Additionally, we assessed treatment, and multifactorial impact on outcomes by Oncotype DX score, including: receipt of chemotherapy, endocrine therapy, stage, and disease-related recurrence and mortality. Results: We identified 2577 eligible patients for the analysis. Black/AA patients had a 49% greater risk/hazard of mortality than non-Hispanic White (NHW) patients (multivariable model p-value 0.0444). Oncotype DX score differences were associated with mortality in the overall sample (multivariable model, p-value = 0.0281). Specifically, in the Oncotype DX-specific models, Black/AA patients with an Oncotype DX score of 0–16 had 73% greater risk of mortality than NHW patients (multivariable model p-value 0.0409). While all other Oncotype DX score categories showed elevated risks of mortality, they were not statistically significant. The Oncotype DX-specific multivariable models showed that, compared to NHW patients, recurrence was lower for Black/AA patients in the lower categories and higher in the upper categories, but results were not statistically significant. Conclusions: This study assessed recurrence and mortality outcomes by the recurrence score and found significantly higher rates of mortality among Black/AA patients in the lowest recurrence score category. Other studies have shown that recurrence scores add prognostic value during diagnosis. However, examining performance of these tools among diverse populations is imperative.

29 May 2026 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
RRRienna G Russo
Rienna G Russo
MHMiguel A Hernán
Miguel A Hernán
IDIssa J Dahabreh
Issa J Dahabreh
EREric B Rimm
Eric B Rimm
LVLene H S Veiga
Lene H S Veiga
JVJacqueline B Vo
Jacqueline B Vo
Background: Limited evidence is available from randomized trials to guide clinical decision making for cardiovascular disease (CVD) prevention with statins among women with breast cancer. We leveraged real-world data to estimate the effect of statin therapy vs usual care on the 5-year risk of CVD among breast cancer survivors. Methods: We sequentially emulated target trials using the National Cancer Institute–Kaiser Permanente Breast Cancer Survivors Cohort. Women aged 40-84 years, diagnosed with stages 0-III breast cancer from 1993 to 2022, without CVD, no statins in the past 6 months, and low-density lipoprotein cholesterol from 100 to 160 mg/dL were included. The outcome was CVD (ischemic heart disease, stroke, and cardiomyopathy/heart failure). We compared statin therapy to usual care (no statins unless indicated) in intention-to-treat and per-protocol analyses. Results: Statin initiators were more likely to be older with a higher prevalence of cardiovascular comorbidities. In the intention-to-treat analysis, the 5-year risk difference was 0.3% (95% CI = −0.9 to 1.5), and risk ratio was 1.04 (95% CI = 0.86 to 1.25) for statin vs usual care. At 5 years, the proportion adherent to their initial strategy was 48% for statin and 24% for usual care. In the per-protocol analysis, the risk difference was −0.9% (95% CI = −2.9 to 2.2) and the risk ratio was 0.85 (95% CI = 0.51 to 1.36) for statin vs usual care. Conclusions: Our findings suggest that statin therapy may reduce the risk of CVD for breast cancer survivors, but the estimates are too imprecise for specific recommendations. Future research is needed to understand reasons for statin discontinuation, and opportunities to encourage adherence in this high-risk population.